{
    "root": "347a9376-5865-d57f-e063-6394a90a4ad4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "IMAAVY",
    "value": "20250506",
    "ingredients": [
        {
            "name": "ARGININE HYDROCHLORIDE",
            "code": "F7LTH1E20Y"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P"
        },
        {
            "name": "METHIONINE",
            "code": "AE28F7PNPL"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "NIPOCALIMAB",
            "code": "87M90CV8NC"
        }
    ],
    "indications": "imaavy indicated treatment generalized myasthenia gravis ( gmg ) adult pediatric patients 12 years age older anti-acetylcholine receptor ( achr ) anti-muscle-specific tyrosine kinase ( musk ) antibody positive .",
    "contraindications": "full prescribing information instructions , preparation , . ( 2.1 , 2.2 , 2.3 ) evaluate need administer age-appropriate vaccines according immunization guidelines initiation imaavy . ( 2.1 ) administer via intravenous infusion . ( 2.2 ) recommended initial 30 mg/kg via intravenous infusion least 30 minutes . two weeks initial , administer maintenance 15 mg/kg via intravenous infusion least 15 minutes , continue every two weeks thereafter . ( 2.2 ) must diluted 0.9 % sodium chloride injection prior . ( 2.3 ) administer intravenous infusion via 0.2 micron in-line add-on filter . ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "imaavy contraindicated patients history serious hypersensitivity reaction nipocalimab excipients imaavy . included anaphylaxis angioedema [ ( 5.2 ) ] .",
    "indications_original": "IMAAVY is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.",
    "contraindications_original": "See Full Prescribing Information for instructions on dosage, preparation, and administration. ( 2.1 , 2.2 , 2.3 ) Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of IMAAVY. ( 2.1 ) Administer via intravenous infusion only. ( 2.2 ) The recommended initial dosage is 30 mg/kg once via intravenous infusion over at least 30 minutes. Two weeks after the initial dosage, administer a maintenance dosage of 15 mg/kg via intravenous infusion over at least 15 minutes, and continue every two weeks thereafter. ( 2.2 ) Must be diluted with 0.9% sodium chloride injection prior to administration. ( 2.3 ) Administer as an intravenous infusion via a 0.2 micron in-line or add-on filter. ( 2.3 )",
    "adverseReactions_original": "IMAAVY is contraindicated in patients with a history of serious hypersensitivity reaction to nipocalimab or any of the excipients in IMAAVY. Reactions have included anaphylaxis and angioedema\n \n  [see\n  \n   Warnings and Precautions (5.2)]\n \n  ."
}